Replay available

Cerus Corporation (CERS) Q4 2025 Earnings Call

Cerus Corporation (NASDAQ: CERS) Q4 2025 earnings conference call, held 2026-03-02. Replay captured from the company's public earnings webcast.

Mon, March 2, 2026 at 4:30 PMendedReplay
Cerus Corporation (CERS) Q4 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Tim Lee

Head of Investor Relations

Obi Greenman

President and Chief Executive Officer

Vivek Jayaraman

Chief Operating Officer

Kevin Green

Chief Financial Officer

Bill Bonello

Analyst, Craig-Hallum Capital

Mark Massaro

Analyst, BTIG

Replay transcript excerpt

Good day, ladies and gentlemen. Thank you for standing by. And welcome to the Cirrus Corporation fourth quarter and full year 2025 earnings conference call. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Tim Lee, Cirrus Head of Investor Relations. Tim, you may begin. Thank you and good afternoon. I'd like to thank everyone for joining us today. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at ir.cirrus.com. With me on the call are Obi Greenman, Cirrus' President and Chief Executive Officer, Vivek Jayaraman, Cirrus' Chief Operating Officer, and Kevin Green, Cirrus' Chief Financial Officer. Cirrus issued a press release today announcing our financial results for the fourth quarter and full year ended December 31st, 2025. The company's recent business highlights and outlook. You can access a copy of the announcement on the company website at www.cirrus.com. I'd like to remind you that some of the statements we'll make on this call relate to future events and performance rather than historical facts and are forward-looking statements. Examples of forward-looking statements include those related to our future financial and operating results, including our 2026 product revenue guidance and our expectations for product gross margin, non-GAAP adjusted EBITDA performance, P&L leverage, and our government-reimbursed R&D expenses and corresponding revenue, expected future growth, the potential for us to reach GAAP profitability, the availability and related timing of data from clinical trials, our mission, to establish Intercept as a global standard of care, plan regulatory submissions, commercial expansion prospe...

More from Cerus Corporation